Briacell Therapeutics Corp BCTX

$4.18 +0.14 (3.47%)

Valuation

Market cap
35,147,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
59,410
Avg volume
325,382
Day's range
$3.94 – $4.22
Shares out
8,700,000
Stochastic %K
23%
Beta
1.21
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

dlev18 Oct 5, 6:54 PM
$BCTX plz make a move
0 replies
BCTX20bMC Oct 5, 2:06 PM
$BCTX added $50K more…GL to me.
1 replies
dlev18 Oct 5, 9:28 AM
$BCTX adding more
0 replies
Biotechlineup Oct 5, 5:20 AM
$BCTX The outcome is always based on the variables that you plug in. Move up to Jan , 15 and you get 99%. Change the control arm, Bria IMT arm or the HR and different outcome. <<Based on the parameters of the Bria-ABC Phase 3 trial, a Monte Carlo simulation (10,000 iterations) was executed using the Python interpreter to model the event accumulation curve between now and December 15, 2026. The model factors in the "hockey stick" enrollment surge from May to October (moving from 180 randomized patients up to near full capacity of 354 patients). It assumes a 1:1 treatment-to-control randomization, a standard historical control median Overall Survival (OS) of 7.5 months, and a targeted Hazard Ratio (HR) of 0.60 for the Bria-IMT arm (resulting in a simulated treatment median OS of 12.5 months). Here are the predictive outcomes of the simulation: 📊 Monte Carlo Simulation Results Probability of Reaching ≥144 Deaths by Dec 15: 97.6% Expected (Average) Event Count by Dec 15: 160 deaths>>
1 replies
JediGreen Oct 5, 12:15 AM
$BCTX https://youtube.com/watch?v=5degIsw-fTI&si=S8fQHFPymvrF4snn
0 replies
AliceFireSteam Oct 3, 6:49 PM
$BCTX latests sims, since there seems to be some interest.
2 replies
smallpower17 Oct 3, 3:56 PM 1 replies
Sb123321 Oct 2, 3:59 PM
$BCTX BCTXZ warrants are priced at a vol of 150%, BCTXL warrants are priced at a vol of 50%. Really doesn't make any sense. You need to buy 10 to convert the BCTXZ into 1 share at a cost of $2.70 ($0.27*10) or buy the lower strike longer life option BCTXL at $1.20. Why are people wasting their money. Do they not understand the conversion terms? If I could gaurantee that I could borrow the XZ (for term) it would be a great arb.
2 replies